Abstract Library

#2897 Comparison of 68Ga-DOTATATE PET/CT for Assessment of Response to Peptide Receptor Radionuclide Therapy after 2 and 4 Cycles of 177Lu-DOTATATE: Preliminary Single Academic Center Experience

Introduction: Peptide receptor radionuclide therapy (PRRT) usually leads to stable rather than decreased lesion size in neuroendocrine tumors (NETs), therefore RECIST criteria are not used to assess early response to treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Song H, Kunz P, Fisher G, Franc B, Moradi F,

Keywords: PRRT, 68Ga-DOTATATE PET/CT, Neuroendocrine tumor,

#2890 Evaluation of Toxicity in Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumors (NET)

Introduction: Peptide receptor radionuclide therapy (PRRT) is an encouraging systemic treatment for neuroendocrine tumors (NET). PRRT is generally safe and possesses little side effects but little is known about liver toxicity.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Duan H

Authors: Duan H, Girod B, Ninatti G, Ferri V, Kunz P,

Keywords: NET, PRRT, Toxicity,

#2866 Extrahepatic 68Ga-DOTATATE-Avid Tumor Volume and Serum Chromogranin A Predict Short-Term Outcome of 177Lu-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Introduction: 177Lu-DOTATATE is an effective therapy for somatostatin receptor-positive neuroendocrine tumors (NETs). Often enough 177Lu-DOTATATE is used as the last treatment resort in advanced NET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Song H, Kunz P, Franc B, Moradi F, Fisher G,

Keywords: 177Lu-DOTATATE, PRRT, 68Ga-DOTATATE PET, Chromogranin A, 68Ga-DOTATATE avid tumor volume,

#1077 Signs of Carcinoid Heart Disease on Staging CT: Which Predictors are Helpful?

Introduction: In patients with functionally active neueroendocrine neoplasms (NEN) carcinoid heart disease presenting primarily with tricuspid valve regurgitation (TR) is associated with high morbidity and mortality. Early diagnosis is crucial to improve prognosis.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Baur A

Authors: Baur A, Kunz F, Pschowski R, Röpke T, Pavel M,

Keywords: computed tomography, staging, carcinoid heart disease,

#792 Phase II Clinical Trial of Pasireotide LAR in Patients with Metastatic Neuroendocrine Tumors

Introduction: Pasireotide LAR is a novel SSA with avid binding to SSTR 1, 2, 3 and 5. It has never been investigated in treatment naïve patients.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Strosberg J

Authors: Cives M, Kunz P, Nguyen P, Jump H, Vilay K,

Keywords: NET, pasireotide, first-line,